DMAC (DiaMedica Therapeutics) Short-Term Debt to Capital

The confirmed price history on this chart demonstrates the 0.00 indicator, while the DiaMedica Therapeutics (DMAC) business relies on non-cyclical, season-independent demand in emergency medicine. Stability is ensured by the humanitarian status of biomedicine and neutrality in global disputes. The company's growth is based on the development of DM199 for renal vessel restoration and the absence of market alternatives.

When constructing a long-term portfolio, it is critical to assess liquidity stability through the ratio of liabilities to equity. This indicator measures the share of short-term loans (up to one year) within the capital structure, identifying the risk of cash flow gaps and dependence on external refinancing. For DiaMedica Therapeutics (DMAC), this is critical, as the development of the DM199 drug depends on clinical test results. The historical trend of the short-term debt-to-equity ratio objectively highlights the issuer's financial strength.